Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
14 hedge funds and large institutions have $19.6M invested in Bellerophon Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
7% less funds holding
Funds holding: 15 → 14 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
45% less capital invested
Capital invested by funds: $35.6M → $19.6M (-$16M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$323K |
| 2 |
LPL Financial
San Diego,
California
|
+$88.7K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$51.4K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$32.6K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.83M |
| 2 |
BG
BlackRock Group
London,
United Kingdom
|
-$76K |
| 3 |
Morgan Stanley
New York
|
-$57.7K |
| 4 |
Goldman Sachs
New York
|
-$53K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$42.9K |
BLPH Hedge Fund Activity: Q4 2015 in Review
14 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2015, worth a combined $19.6M — down 45% from $35.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BLPH and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $323K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.83M sold.
- 14 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2015, down from 15 in Q3 2015.
- Funds reported $19.6M of Bellerophon Therapeutics, Inc. stock for Q4 2015, down 45% quarter-over-quarter.
- 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2015 and 4 closed out, a net change of -1 holder.
- The largest Bellerophon Therapeutics, Inc. buyer in Q4 2015 was Bridgeway Capital Management, an estimated $323K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q4 2015 was Baker Bros. Advisors, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2015.